Back to results
US 5,686,408 AGranted
Method for modifying, diagnosing, and screening for IGF-I sensitive cell barrier properties
AssigneeThe Beth Israel Hospital Association
InventorsAlan C. Moses, Linda A. Morrow, Jeffrey S. Flier
Life of this patent
Estimating the term…
Abstract
A method of chronic modification of cell barrier properties by exposing a cell to a modification-effective amount of IGF-I for at least about 7 days wherein the modification effective amount is between about 50 .mu.g/kg and less than about 500 .mu.g/kg is disclosed. Further disclosed is a method of chronic amelioration or reversal of insulin resistance as well as a method of diagnosing and screening for rhIGF-I sensitive cell barrier properties.
Claims10
A method of chronic post administration modification of glucose or insulin levels which method comprises:
- (a) obtaining a pre-exposure indicator level value for levels of an indicator selected from the group consisting of glucose and insulin to establish a pre-exposure baseline value;
- (b) exposing a cell to a modification-effective amount of IGF-I for at least about 7 days to about 31 days;
- (c) obtaining a post-exposure indicator level value for levels of an indicator selected from the group consisting of glucose and insulin after IGF-I exposure has ceased;
- and
- (d) comparing the post-exposure indicator level value from step (c) with the pre-exposure indicator level value from step (a), where a post-exposure indicator level value greater than or less than, as appropriate to the indicator chosen, the pre-exposure baseline value for a period of at least about seven days after IGF-I exposure has ceased is indicative of chronic modification of glucose or insulin levels.
2 more elements
Dependencies are inferred from the claim text.